Latest news with #Healthcare
Yahoo
7 hours ago
- Business
- Yahoo
Medical Coating Market worth $15,813.6 million by 2030 - Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., July 22, 2025 /PRNewswire/ -- The report " Medical Coatings Market by Coating Type (Active, Passive), By Material (Polymers, Metals), By Application (Medical Devices, Medical Implants, Medical Equipment & Tools), By Region – Global Forecast to 2030 ", medical coating market size is projected to reach 15,813.6 million by 2030 at a CAGR of 9.6% from USD 9,983.0 million in 2025. Factors contributing to the medical coating market include the rising prevalence of chronic diseases, increased demand for advanced medical devices, and a growing geriatric population. Other factors driving the adoption and innovation of medical coatings include improved infection control, the growth of minimally invasive procedures, and shorter trial studies related to regulatory requirements for biocompatibility. Browse in-depth TOC on "Medical Coating Market" 300 - Tables 50 - Figures 179 - Pages Download PDF Brochure: Metals will account for the second-largest share in the medical coating market by material during the forecast period, in terms of value. Metals are expected to hold the second-largest share of the medical coating market, by material, during the forecast period, in terms of value. Metals possess key attributes such as strength, combined with advantageous biocompatibility and durability, making them ideal for high-performance medical devices like orthopaedic implants and cardiovascular stents. Metals like silver and titanium have unique antimicrobial properties that help reduce infection risk inherently when used in implants and bearings. The growth in demand for metal coatings during this period is driven by advances in surface modification technologies and an increasing need for infection control within healthcare organizations. Medical implants will be the second-fastest-growing application in the medical coating market during the forecast period, in terms of value. During the forecast period, medical implants are the second fastest-growing application in the medical coating market in terms of value, mainly due to the rising prevalence of chronic diseases and the rapidly aging global population. Advances in biomaterials and coating technologies are also making implants safer and more durable with improved biocompatibility. In addition to these safety improvements, the increasing demand for orthopaedic, cardiovascular, and dental implants has driven growth across the market. Regulatory approvals and higher healthcare spending have likely supported this trend. Request Sample Pages: Europe accounts for the second-largest share in the medical coating market in terms of value. Europe holds the second-largest share by value in the medical coating market, after North America, thanks to the region's well-developed healthcare infrastructure and large medical device manufacturing base. The region is characterized by strict regulatory environments like the EU Medical Device Regulation (MDR) and a strong focus on infection prevention, control, and AM coatings. Countries such as Germany, France, and the United Kingdom are the main demand drivers for coated devices, especially those related to cardiovascular and orthopaedic applications. Additionally, rising healthcare expenditures and the rapid expansion of wearable technologies are boosting the industry's growth across Europe. Request Customization: Key Players Acquisitions and expansions serve as the main growth strategies used by leading companies in the market. The major global players in the medical coating industry include Hydromer (US), DSM-Firmenich (Netherlands), Surmodics (US), Biocoat Incorporated (US), AST Products Inc (US), Covalon Technologies (Canada), Freudenberg Medical (US), Harland Medical Systems, Inc (US), Merit Medical Systems (US), Applied Medical Coatings (US), PPG Industries, Inc. (US), and The Sherwin-Williams Company (US). Get access to the latest updates on Medical Coating Companies and Medical Coating Market Size Browse Adjacent Market: Coatings Adhesives Sealants & Elastomers Research Reports & Consulting Related Reports: Antimicrobial Coatings Market - Global Forecast to 2027 Thermal Spray Coatings Market - Global Forecast to 2028 Textile Coatings Market - Global Forecast to 2028 ETFE & ECTFE Coatings Market - Global Forecast to 2030 Industrial Coatings Market - Global Forecast to 2030 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
9 hours ago
- Business
- Yahoo
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health and Community Health Systems
For Immediate Release Chicago, IL – July 22, 2025 – Today, Zacks Equity Research discusses HCA Healthcare, Inc. HCA, Tenet Healthcare Corp. THC, Universal Health Services, Inc. UHS and Community Health Systems, Inc. CYH. Industry: Hospitals Link: The Zacks Medical-Hospital industry faces mounting challenges, including rising labor costs, supply expenses, regulatory pressures and tightening budgets. Workforce burnout and cybersecurity risks continue to strain operations, while technological innovations offer long-term efficiency gains. Despite near-term headwinds, growing patient volumes may support gradual through mergers and acquisitions remains a key strategy, allowing hospitals to scale operations and increase market share in a fragmented landscape. Leading players HCA Healthcare, Inc., Tenet Healthcare Corp., Universal Health Services, Inc. and Community Health Systems, Inc. are demonstrating resilience by optimizing operations and expanding strategically to stay competitive in a complex and evolving healthcare environment. Industry Overview The Zacks Medical-Hospital industry comprises for-profit hospital companies that provide healthcare through different types of hospitals, such as acute care, rehabilitation and psychiatric. These hospital entities are engaged in internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, telehealth services, mental health care and diagnostic and emergency services. Revenues of these companies depend on inpatient occupancy levels, medical and ancillary services ordered by physicians and provided to patients, and the volume of outpatient procedures. These hospital companies receive payments for patient services from the government under the Medicare program, Medicaid, or similar programs, managed care plans (including plans offered through the American Health Benefit Exchanges), private insurers and directly from patients. 4 Key Trends to Watch in the Hospital Industry Elective procedures are on the rise, contributing to increased patient volumes across hospitals. U.S. Census Bureau projections show the 65+ population will grow from 17.3% in 2022 to 22.8% by 2050, amplifying demand for healthcare. Health spending is projected to hit $5.3 trillion by 2025, according to the Peterson-KFF Health System Tracker. However, technological advancements are likely to accelerate a shift from inpatient care to outpatient, ambulatory and home-based services, leaving many hospitals with underused beds and a heavy fixed-cost burden. Labor shortage, higher wages, supply chain disruptions and escalating benefit costs continue to squeeze hospital margins. In response, providers are embracing automation, refining staffing models, and renegotiating supplier contracts to manage expenses. Efforts to reduce reliance on contract labor are gaining traction, although burnout challenges persist. Meanwhile, cybersecurity threats are prompting higher insurance premiums, adding to financial strain. A new $50 billion federal fund aims to support rural and underserved hospitals, but several experts note it may fall short of covering broader funding gaps tied to Medicaid reimbursement changes. Hospitals are investing heavily in AI, automation, and real-time analytics to streamline care delivery and reduce operational inefficiencies. These tools are improving clinical outcomes, enhancing patient engagement, and supporting long-term cost savings. Simultaneously, telehealth, accelerated by the pandemic, has become a permanent and vital component of care, particularly for remote and underserved populations. M&A activity has rebounded strongly post-pandemic, as hospitals seek scale, efficiency, and financial resilience. With the industry still highly fragmented, consolidation is being driven by economic recovery, regulatory clarity and the need to adapt to changing care models. Strategic partnerships, technology-driven collaborations, and innovative delivery models are helping hospitals expand capacity and sharpen their competitive edge. Zacks Industry Rank Shows Bearish Outlook The group's Zacks Industry Rank, which is the average of the Zacks Rank of all member stocks, signals challenging near-term prospects. The Zacks Medical-Hospital industry, which is housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #181, which places it in the bottom 26% of nearly 250 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one. The industry's position in the bottom 50% of the Zacks-ranked industries is a result of a negative earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are becoming pessimistic about this group's earnings growth potential. As a matter of fact, the industry's earnings estimates for 2025 have gone down 0.2% since February-end. Despite the dull near-term prospects of the industry, we will present a few stocks that you may want to watch. But it's worth taking a look at the industry's shareholder returns and current valuation first. Industry Lags S&P 500 But Outperforms Sector The Zacks Medical-Hospital industry has underperformed the Zacks S&P 500 composite while outperforming the broader Medical sector in a year. The industry has gained 4.2% over this period, underperforming the S&P 500's appreciation of 13.1% and outperforming the broader sector's slide of 17.6%. Industry's Current Valuation On the basis of the trailing 12-month EV/EBITDA (Enterprise Value/ Earnings Before Interest Tax Depreciation and Amortization) ratio, which is commonly used for valuing hospital stocks, the industry trades at 7.84X compared with the S&P 500's 17.79X and the sector's 9.72X. Over the past five years, the industry has traded as high as 9.55X and as low as 6.45X, with a median of 8.03X. 4 Hospital Stocks Worth Your Attention HCA Healthcare: The company operates general and acute care hospitals and is well-positioned to benefit from rising patient volumes. Growth in inpatient surgeries, ER visits, and telemedicine is boosting performance and diversifying revenue. Strategic acquisitions and ongoing dividends and buybacks reflect its focus on expansion and shareholder returns. The Zacks Consensus Estimate for one of the biggest for-profit publicly traded hospitals' 2025 EPS indicates 15% year-over-year growth. HCA Healthcare beat earnings estimates in each of the past four quarters, the average surprise being 7.1%. The consensus mark for 2025 revenues signals a 5.7% increase from a year ago. Shares of the company have gained 20.3% over the year-to-date period. It currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Tenet Healthcare Corporation: The company operates a wide network of hospitals and facilities, with strong revenue growth driven by its Ambulatory Care and Hospital segments. The USPI unit remains a core growth engine, supported by strategic tuck-in acquisitions that continue to enhance its market position. The Zacks Consensus Estimate for Tenet Healthcare's 2025 and 2026 bottom line indicates 7.2% and 7% year-over-year growth. It beat earnings estimates in all the past four quarters, the average surprise being 26.4%. The consensus mark for 2025 and 2026 revenues is pegged at $20.9 billion and $21.9 billion, signaling an increase from $20.7 billion in 2024. Shares of the company have gained 38.7% over the year-to-date period. It currently has a Zacks Rank #3. Universal Health Services: The company operates acute care hospitals, outpatient centers, and behavioral health facilities, with specialties including autism, addiction, and military-related conditions. Growth is supported by rising patient days, network expansion, added licensed beds and strategic behavioral health joint ventures. The Zacks Consensus Estimate for Universal Health's 2025 and 2026 bottom line is pegged at $19.43 and $21.10 per share, respectively, up 17% and 8.6% year over year, respectively. It beat earnings estimates in three of the past four quarters and missed once, the average surprise being 13.8%. The consensus mark for 2025 and 2026 revenues indicates 8% and 5.2% year-over-year increases. Although shares of Universal Health have declined 5.9% over the year-to-date period, its improving operations are expected to support a future rebound. It currently sports a Zacks Rank #3. Community Health Systems: It operates a national network of acute care hospitals and outpatient centers, benefiting from higher occupancy rates and a growing telehealth focus. It is expanding through hospital acquisitions, enhancing specialty services, and improving efficiency. Strategic divestments of non-core assets aim to boost long-term profitability and cash flow, despite potential short-term impact. The Zacks Consensus Estimate for Community Health Systems' 2025 and 2026 bottom lines indicates 69.9% and 142.1% year-over-year improvements, respectively. The consensus mark for 2025 and 2026 revenues is pegged at $12.3 billion and $12.8 billion, respectively. Shares of Community Health Systems have gained 20% in the past week. It has a Zacks Rank #3 at present. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Universal Health Services, Inc. (UHS) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Community Health Systems, Inc. (CYH) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Wall Street Journal
21 hours ago
- Health
- Wall Street Journal
Meet the Medicaid Double-Dippers
Democrats haven't taken a breath since the Republican budget bill passed, trying to scare Americans across the country that millions are about to lose Medicaid coverage. You won't read this elsewhere, but the government has now found that up to 2.8 million Americans are enrolled in two separate health plans underwritten by taxpayers. The Centers for Medicare and Medicaid Services (CMS) reported late last week that 1.2 million Americans last year were enrolled in Medicaid or the Children's Health Insurance Program in two or more states. The agency worked with software engineers to review enrollment data, and it found another 1.6 million enrolled in both Medicaid and an ObamaCare plan with taxpayer subsidies in 2024.
Yahoo
a day ago
- Business
- Yahoo
[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cardiac Tissue Engineering Market size & share revenue was valued at approximately USD 632.10 Million in 2024 and is expected to reach USD 735.98 Million in 2025 and is expected to reach around USD 2,943.92 Million by 2034, at a CAGR of 16.65% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott Laboratories, Artivion Inc., Athersys Inc., Baxter International Inc., Cellular Logistics Inc., Elutia Inc., Heartseed Inc., Medtronic Plc, Merck kGaA, Mesoblast Ltd., Neoolife Inc., Tejiin Limited, Terumo Corporation, and W.L. Gore & Associates, Inc and others. Austin, TX, USA, July 21, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Cardiac Tissue Engineering Market Size, Trends and Insights By Material (Scaffold, Stem Cells), By Product (Heart Valve, Vascular Grafts), By Application (MI, Congenital Heart Disease), By Distribution Channel (Hospitals & Clinics, Academics & Research Institutes), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of the global Cardiac Tissue Engineering Market size & share was valued at approximately USD 632.10 Million in 2024 and is expected to reach USD 735.98 Million in 2025 and is expected to reach a value of around USD 2,943.92 Million by 2034, at a compound annual growth rate (CAGR) of about 16.65% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Cardiac Tissue Engineering Market @ Overview According to industry experts at CMI, the implementation of new strategies and technologies by manufacturers presents lucrative opportunities for players in the Cardiac Tissue Engineering Market during the forecast period. Furthermore, the growing significance of organized retailing is expected to drive the future growth of the market. Key Trends & Drivers Integration of 3D Bioprinting in Cardiac Tissue Fabrication: 3D bioprinting has reshaped the cardiac tissue engineering market as it enables the precise fabrication of the heart tissue using the layer by layer deposition of the bioinks containing cells and biomaterials. This enables the development of customized cardiac grafts with anatomy that closely corresponds to native tissue architecture and function. Bioprinted cardiac patches and vascular networks demonstrate superior cell viability, integration with tissues, and scalability. Along with improvement in printing methods, this allows for mass production of grafts that are tailor-made for specific patients, hence minimizing the use of donor tissue. This trend is gathering pace in both research and clinical spheres, whereby it fosters innovation at the forefront of regenerative cardiovascular interventions. Advances in Stem Cell and iPSC Technology: The development of the Induced Pluripotent Stem Cell (iPSC) Technology along with the fine-tuning is expected to boost the growth of the cardiac tissue engineering market. iPSCs provide an ethically acceptable cardiomyocyte and vascular cell source from among the variety of patients for engineered tissues. Their resemblance to natural development and responsiveness to external stimuli being suitable traits for regeneration applications further add to their idealness. The ongoing research is enhancing reprogramming and differentiation protocol efficiency as well as augmenting the maturity and functionality of cardiac cells. Thus, such innovations even help in reducing immune rejection and conform to patient-oriented therapies, making stem cell technology one of the weighing stones in the turn toward cardiac tissue engineering solutions. Rising Utilization of Smart Scaffolds and Bioactive Scaffolds: Smart scaffolds that respond to physiological stimuli for the release of bioactive molecules into the cardiac tissue engineering field are transforming its scope. These advanced scaffolds provide structural support to the cells but also aid in their attachment, proliferation, and differentiation by mimicking the extracellular matrix of the heart. Nanotechnology and material science innovations are ensuring scaffolds with better conductivity, biodegradability, and mechanical properties. Bioactive scaffolds with growth factors or signalling peptides further augment tissue regeneration. The use of such intelligent materials in enhancing the therapeutic efficacy is a major trend leading to the development of the next-generation functional implantable cardiac constructs. Request a Customized Copy of the Cardiac Tissue Engineering Market Report @ Rise of Regenerative Cardiology for Pediatric Care Applications: This burgeoning need for regenerative solutions in pediatric cardiology is one of the main prevailing trends in cardiac tissue engineering space. Children afflicted with congenital heart defects require multiple surgeries because synthetic grafts and valves do not grow with the body. Tissue-engineered heart valves and patches, produced with heart cells derived from autologous cells, offer the possibility of growth, remodeling, and natural integration within the child's cardiovascular system. This advancement reduces the frequency of repeated interventions and improves long-term outcomes. Fueled by heightened research focus and enabled by regulatory pathways for pediatric therapies, this trend is accelerating the clinical translation of engineered solutions in pediatric cardiac care. Expansion of Clinical Trials and Translational Research: The surge in the clinical trials along with the translational research provides progress in the cardio tissue engineering solutions from lab-to-bedside. The academic institutions along with the startups and pharmaceutical companies are investing in the phase I/II trials for the safety and efficacy evaluations of the engineered heart tissue along with patches and valves. These trials are required for regulatory approvals and commercialization strategies. Collaboration between research centers and hospitals is ongoing to aid trial design and patient recruitment. This trend reflects renewed confidence in regenerative cardiac therapies and is a prerequisite for building clinical evidence, which then attracts funding and accelerates broader acceptance of the technology in the market. Personalized and Precision Cardiac Regeneration Therapies: The personalized medicines are transforming cardiac tissue engineering as they enable treatments based on the patient's genetic and physiological profiles. In this way, better understanding is achieved of the causes and mechanisms of diseases by means of the number of genomics, proteomics, and data analytic techniques, which direct the manufacturing of cardiac constructs with cells cultured from patients. Thus, these therapies stand against immune rejection on the physician's side, and they also keep the compatibility and healing of the patient in consideration. Precision methods like CRISPR are also being evaluated as options to target genetic mutations ahead of tissue engineering applications. Patient-specific approaches to healing are further improving treatment, strengthening cardiac functionality for the long run, and embracing wider trends within precision healthcare, in alignment with thereby sustaining the growth of the market. Report Scope Feature of the Report Details Market Size in 2025 USD 735.98 Million Projected Market Size in 2034 USD 2,943.92 Million Market Size in 2024 USD 632.10 Million CAGR Growth Rate 16.65% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Material, Product, Application, Distribution Channel and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Cardiac Tissue Engineering report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Cardiac Tissue Engineering report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Cardiac Tissue Engineering Market Report @ SWOT Analysis Strengths: Cardiovascular diseases (CVDs) are the leading cause of death globally. Heart failure, often resulting from myocardial infarction (heart attack) and the limited regenerative capacity of the adult heart, represents a significant clinical challenge. The increasing incidence of CVDs globally, driven by aging populations, lifestyle factors, and comorbidities like diabetes and obesity, ensures a continuously expanding patient pool requiring advanced treatments. Weakness: The development of cardiac tissue engineering therapies involves extensive, complex, and costly research & development phases. Replicating the intricate, anisotropic structure, electrical conductivity, synchronized contraction, and robust vascularization of native human heart tissue is extremely challenging. Ensuring adequate vascularization (blood supply) within thick engineered cardiac tissues is critical for their survival and function in vivo. Opportunities: The demographic shift towards an older population, coupled with the rising global burden of cardiovascular diseases, ensures a growing demand for advanced cardiac therapies. Continued progress in induced pluripotent stem cells (iPSCs) and other stem cell sources for generating cardiomyocytes offers more patient-specific and less immunogenic cell sources for tissue engineering. Continued government funding for regenerative medicine and rising healthcare expenditure, particularly in developed nations, will fuel market growth. Threats: The high risk associated with clinical trials for novel therapies means that any major setback or failure could severely damage market confidence and delay progress. The use of stem cells and the creation of 'living' tissues raise ethical considerations that could impact public acceptance and regulatory frameworks. The highly innovative nature of the market could lead to complex intellectual property disputes among research institutions and companies. Request a Customized Copy of the Cardiac Tissue Engineering Market Report @ Key questions answered in this report: What is the size of the Cardiac Tissue Engineering market and what is its expected growth rate? What are the primary driving factors that push the Cardiac Tissue Engineering market forward? What are the Cardiac Tissue Engineering Industry's top companies? What are the different categories that the Cardiac Tissue Engineering Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Cardiac Tissue Engineering market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Cardiac Tissue Engineering Research Report | Fast Delivery Available - [220+ Pages] @ Regional Analysis The Cardiac Tissue Engineering Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region: North America: North America dominates the cardiac tissue engineering market due to advanced healthcare infrastructure, robust R&D investments, and a high prevalence of cardiovascular diseases. Strong support from government bodies, leading academic institutions, and a concentration of biotech firms fuel innovation in regenerative therapies. The United States holds the largest share of the cardiac tissue engineering market in North America, driven by a well-established healthcare system, world-class research institutions, and high patient demand for innovative treatments. The country is home to major biotech firms and academic centers leading clinical trials in cardiac regeneration. Europe: Europe is a key player in the cardiac tissue engineering market, supported by strong academic research, growing healthcare investments, and progressive regulatory frameworks. Countries like Germany, the UK, and the Netherlands are at the forefront of regenerative medicine innovation. Collaborative projects across universities, hospitals, and biotech firms drive the development of tissue-engineered heart valves, grafts, and myocardial patches. The European Medicines Agency (EMA) provides structured pathways for approval, enhancing clinical translation. With an aging population and a high incidence of cardiovascular conditions, Europe's demand for effective, regenerative cardiac therapies continues to rise, fostering steady market expansion across the region. Asia-Pacific: The Asia-Pacific region presents immense growth potential in the cardiac tissue engineering market due to its large patient population, rising cardiovascular disease burden, and increasing healthcare expenditure. Countries like China, Japan, South Korea, and India are investing heavily in biotechnology and regenerative medicine research. Government initiatives, growing collaborations with global players, and an expanding network of research institutions are driving innovation in the field. Additionally, lower clinical trial costs and favorable demographic trends are attracting companies to conduct studies and expand their footprint in the region. The rapid adoption of advanced medical technologies positions Asia-Pacific as a growing market hub. LAMEA: The LAMEA (Latin America, Middle East, and Africa) region is an emerging market for cardiac tissue engineering, with gradual improvements in healthcare infrastructure and growing awareness of regenerative therapies. Countries like Brazil, South Africa, and the UAE are beginning to invest in advanced medical research and adopt innovative treatment modalities. While market penetration is still in its early stages, increasing incidences of heart disease and collaborations with international research organizations are paving the way for development. Despite challenges like limited funding and regulatory barriers, the region shows long-term potential as local governments and institutions prioritize cardiovascular health. Request a Customized Copy of the Cardiac Tissue Engineering Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detailed Information: support@ Browse the full 'Cardiac Tissue Engineering Market Size, Trends and Insights By Material (Scaffold, Stem Cells), By Product (Heart Valve, Vascular Grafts), By Application (MI, Congenital Heart Disease), By Distribution Channel (Hospitals & Clinics, Academics & Research Institutes), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the Cardiac Tissue Engineering Market: Abbott Laboratories Artivion Inc. Athersys Inc. Baxter Internatioal Inc. Cellular Logistics Inc. Elutia Inc. Heartseed Inc. Medtronic Plc Merck kGaA Mesoblast Ltd. Neoolife Inc. Tejiin Limited Terumo Corporation L. Gore & Associates Inc. Others Click Here to Access a Free Sample Report of the Global Cardiac Tissue Engineering Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: CRISPR and Cas Genes Market: CRISPR and Cas Genes Market Size, Trends and Insights By Technology Type (CRISPR/Cas9, CRISPR/Cas13, CRISPR/Cas14, Others), By Delivery Method (Ex vivo, In vivo, Physical Methods, Others), By Application Area (Functional Genomics, Oncology, Infectious Diseases, Others), By Tool Type (Guide RNA, CRISPR Plasmids, Cas Nucleases, Custom CRISPR Libraries, Vectors & Cloning Kits), By Crop Type (Cereals & Grains, Fruits & Vegetables, Oilseeds & Pulses, Industrial Crops), By Disease Type (Cancer, Blood Disorders, Ophthalmic Diseases, Infectious Diseases, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Y Chromosome Microdeletion Detection Kit Market: Y Chromosome Microdeletion Detection Kit Market Size, Trends and Insights By Product Type (PCR-based Kits, FISH-based Kits, Others), By Application (Hospitals, Diagnostic Laboratories, Research Institutes, Others), By End-User (Healthcare Providers, Research Laboratories, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 CRISPR Gene Editing Market: CRISPR Gene Editing Market Size, Trends and Insights By Product (Kits and Reagents, Services), By Gene Editing Modality (Ex-Vivo Editing, In-Vivo Editing), By Technology (CRISPR/Cas9 Technology, CRISPR/Cas12 Technology, Prime Editing, Epigenetic Editing, Others), By Application (Therapeutic Applications, Agriculture and Livestock, Industrial Biotechnology), By End User (Biotechnology and Pharmaceutical Companies, Agricultural and Livestock Industry, Hospitals and Clinics, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Pneumothorax Treatment Market: Pneumothorax Treatment Market Size, Trends and Insights By Type (Primary Spontaneous, Secondary Spontaneous, Latrogenic, Injury Related, Catamenial), By Treatment (Medication, Antibiotics, Benzodiazepines, Opiate anesthetics, Others), By Diagnosis (Chest X-ray, Computerized Tomography Scan, Ultrasound, Physical Examination), By End-User (Hospitals, Clinics, Ambulatory Distribution Channel), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 VATS Instruments Market: VATS Instruments Market Size, Trends and Insights By Type (Forceps, Scissors, Clamps, Needle Holders, Others), By Application (Hospital, Clinic, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Japan Tissue Engineering Market: Japan Tissue Engineering Market Size, Trends and Insights By Type (Synthetic Scaffold Material, Biologically Derived Scaffold Material, Others), By Application (Orthopedics and Musculoskeletal, Neurology, Cardiovascular, Skin and Integumentary, Dental, Others), By End user (Hospitals and Clinics, Ambulatory Facilities), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Inferior Vena Cava IVC Filter Market: Inferior Vena Cava IVC Filter Market Size, Trends and Insights By Product Type (Retrievable Inferior Vena Cava filters, Permanent Inferior Vena Cava Filters), By Material (Non-Ferromagnetic Material, Ferromagnetic Materials), By Application (Treatment of Venous Thromboembolism, Prevention of Pulmonary Embolism), By End Users (Hospitals, Ambulatory Surgical Centers, Emergency Care Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Plant Tissue Culture Market: Plant Tissue Culture Market Size, Trends and Insights By Crop Type (Banana Plants, Floriculture Plants, Wood Producing Plants, Fruit Plants, Vegetable Plants, Ornamental Plants, Aquatic Plants, Others), By Stage (Explant preparation and Inoculation, Multiplication, Hardening), By Plant Type (Annual Plants, Biennial Plants, Perennial Plants), By Type of Media (Murashige and Skoog Media, Linsmaier and Skoog Media, Others), By Type of Growth Container (Test Tubes and Petri Dishes, Glass Bottles, Plastic Containers), By Application (Agriculture, Research, Gardening and Decoration, Forestry and Botanical Garden), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 The Cardiac Tissue Engineering Market is segmented as follows: By Material Scaffold Stem Cells By Product Heart Valve Vascular Grafts By Application MI Congenital Heart Disease By Distribution Channel Hospitals & Clinics Academics & Research Institutes Click Here to Get a Free Sample Report of the Global Cardiac Tissue Engineering Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Cardiac Tissue Engineering Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This Cardiac Tissue Engineering Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Cardiac Tissue Engineering Market? What Was the Capacity, Production Value, Cost and PROFIT of the Cardiac Tissue Engineering Market? What Is the Current Market Status of the Cardiac Tissue Engineering Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Cardiac Tissue Engineering Market by Considering Applications and Types? What Are Projections of the Global Cardiac Tissue Engineering Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Cardiac Tissue Engineering Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Cardiac Tissue Engineering Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Cardiac Tissue Engineering Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Cardiac Tissue Engineering Industry? Click Here to Access a Free Sample Report of the Global Cardiac Tissue Engineering Market @ Reasons to Purchase Cardiac Tissue Engineering Market Report Cardiac Tissue Engineering Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Cardiac Tissue Engineering Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Cardiac Tissue Engineering Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Cardiac Tissue Engineering Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Cardiac Tissue Engineering market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Cardiac Tissue Engineering Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Cardiac Tissue Engineering market analysis. The competitive environment of current and potential participants in the Cardiac Tissue Engineering market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Cardiac Tissue Engineering market should find this report useful. The research will be useful to all market participants in the Cardiac Tissue Engineering industry. Managers in the Cardiac Tissue Engineering sector are interested in publishing up-to-date and projected data about the worldwide Cardiac Tissue Engineering market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Cardiac Tissue Engineering products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Cardiac Tissue Engineering Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Cardiac Tissue Engineering Research Report | Fast Delivery Available - [220+ Pages] @
Yahoo
a day ago
- Business
- Yahoo
Organ Preservation Market worth $0.3 billion by 2030 with 6.8% CAGR
DELRAY BEACH, Fla., July 21, 2025 /PRNewswire/ --The global Organ Preservation Market, valued at US$0.1 billion in 2024 stood at US$0.2 billion in 2025 and is projected to advance at a resilient CAGR of 6.8% from 2025 to 2030, culminating in a forecasted valuation of US$0.3 billion by the end of the period. The organ preservation market is experiencing robust growth fueled by rising incidence of chronic diseases, organ failure, and advancements in transplantation procedures. Increasing rates of end-stage organ conditions—such as kidney, liver, and heart failure—combined with a growing global demand for transplant procedures are key factors accelerating market expansion. The aging population, more susceptible to organ dysfunction, further highlights the increasing need for effective preservation methods to maintain organ viability pre-transplantation. Technological progress in preservation techniques, including hypothermic and normothermic perfusion, is transforming the standard of care by enhancing organ function and extending preservation times. In parallel, developing innovative preservation solutions such as the University of Wisconsin (UW) solution and Custodiol HTK significantly improves transplantation outcomes. Rising awareness among healthcare providers and the public about timely organ donation and preservation is increasing product adoption. Expanding hospital transplant programs, supportive government initiatives, and improved healthcare infrastructure in emerging markets also drive market momentum. Download PDF Brochure: Browse in-depth TOC on "Organ Preservation Market" 300 - Tables 100 - Figures 400 - Pages By solution, the organ preservation market, by solution, is categorized into UW Solution, Custodial HTK, Perfadex, and other solutions (including EuroCollins and Celsior). The UW (University of Wisconsin) solution accounted for the largest market share in 2024. This solution is widely used for preserving and flushing organs such as the liver, kidneys, and pancreas. As the first intracellular solution introduced for this purpose, it has become the benchmark in organ preservation. The dominance of the UW solution can be credited to its high efficacy in improving transplant outcomes. This is primarily due to the inclusion of metabolically inactive compounds like lactobionate and raffinose, which help reduce tissue damage, maintain cellular integrity, and enhance the physiological viability of organs during storage. These advantages have made the UW solution preferred over alternative preservation media. By technique, the static cold storage segment is expected to dominate the market due to its simplicity, cost-effectiveness, and widespread use in preserving kidneys, liver, and pancreas. While newer technologies such as hypothermic machines and normothermic perfusion are gaining traction, especially for heart and lung preservation, static cold storage remains the gold standard in many transplant centers worldwide. In addition, ongoing advancements in perfusion technologies and a growing focus on organ quality optimization before transplantation are expanding the market. The increasing initiatives by governments and non-profits to promote organ donation, along with improvements in preservation solutions and transportation logistics, are further contributing to market growth. As the demand for transplantable organs continues to outpace supply, efficient and advanced preservation methods become more crucial in ensuring transplant success. By organ type, Organ preservation, categorized by organ type, includes kidneys, liver, lungs, heart, and pancreas. In 2024, the kidney segment emerged as the leading contributor to the market. This prominence is primarily due to the rising prevalence of end-stage renal disease (ESRD), for which kidney transplantation remains the most effective treatment option. As kidney failure cases continue to grow, so does the number of transplant procedures, necessitating efficient preservation of donor kidneys before implantation in recipients. By end user, the organ preservation market is divided into transplant centers, hospitals, and specialty clinics. In 2024, the organ transplant centers segment accounted for the largest share of the market. The large share of this segment can be attributed to the extensive establishment of healthcare facilities that operate dedicated transplant programs. These centers are central to organ retrieval, preservation, and transplantation, making them critical consumers of preservation products and technologies. By geography, The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The high growth rate of the Asia Pacific region is attributed to supportive government policies, rising public awareness regarding organ donation, and a surge in organ donation activities. Countries like China and Japan have implemented standardized national guidelines for organ donation and transplantation, which are playing a key role in advancing the market. Additionally, improvements in healthcare infrastructure, the increasing burden of chronic illnesses, and the rise of medical tourism across several countries in the region are expected to fuel the market growth during the forecast period. Request Sample Pages : The prominent players in the global organ preservation market are Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), Global Transplant Solutions (US), Avionord (Italy), Organ Preservation Solutions (England), EBERS (Spain), S.A.L.F. (Italy), Biochefa (Poland), Vascular Perfusion Solutions, Inc. (US), and TX Innovations (Netherlands). Paragonix (US): Paragonix is the leading market player in organ preservation. It operates mainly in the US and Europe. The company has been focused on developments such as new product launches, partnerships, agreements, and approvals since 2016. The company has developed devices for all thoracic & abdominal organ preservation. Paragonix also focuses on software services and tools for real-time organ tracking. Paragonix partnered with the Lung Transplant Foundation (US) to develop various technologies to improve donor lung preservation. In January 2021, the company partnered with Southwest Transplant Alliance (STA) to provide advanced organ preservation technologies. Such a development proves the company's strong market prevalence. XVIVO Perfusion AB (Sweden) XVIVO Perfusion AB is a prominent market and public domain company. It is headquartered in Sweden and operates in Europe, Asia, the Middle East, and North & South America. It spends nearly 31% of its revenue on R&D, which is why the company is involved in developing improved products for organ perfusion. XVIVO's lung perfusion solution is used mainly in Lung Preservation, making the solution a gold standard. In September 2020, XVIVO Perfusion entered an acquisition agreement with Organ Assist. This agreement further strengthened the company's product range and expanded its addressable market. Dr. Franz Kohler Chemie GmbH (Germany) Dr. Franz Kohler Chemie GmbH is a leading market player in organ preservation solutions since 1959. It involves developing electrolyte solutions, organ-protective solutions, therapeutics, antidotes, X-ray contrast agents, and medical devices. It has captured the market for Custodial, an organ preservation solution. Custodial holds advantages over other solutions, like reduced viscosity and an improved graft survival rate, and is widely used to preserve all organs, unlike other solutions. These advantages of a Custodial solution for organ preservation prove that Dr. Franz Kohler Chemie GMBH holds a substantial market prevalence. For more information, Inquire Now! Related Reports: Biopreservation Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Electrophysiology Market Human Organoids Market Transplant Diagnostics Market Get access to the latest updates on Organ Preservation Companies and Organ Preservation Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
